Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership
8.1.2025 08:00:00 CET | ACCESS Newswire | Press release
HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.
The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of services will allow Champions to better serve its clients by offering increased depth through higher complexity spectral analysis. Champions is also pleased to welcome Troy Tremaine, who will lead the commercial strategy for this growing business vertical. As a seasoned leader in this field, Troy brings decades of experience in commercial leadership within the preclinical and bioanalytical space, across multiple therapeutic areas.
"We're thrilled about the investments we are making in our Bioanalytical Services offerings," said Ronnie Morris, CEO of Champions Oncology. "The Cytek Aurora instruments will enhance our competitiveness as we continue to expand in this large market. We are also very excited to have Troy join our team. His extensive track record of success in this field will be invaluable as we grow this business."
About Champions Oncology
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Rachel Bunting, MS, MBA
VP, Global Marketing
Marketing@ChampionsOncology.com
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View the original press release on accesswire.com
Champions Oncology, Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
TruMerit and Credivera Issue First Verifiable Digital Credentials for Global Healthcare Professionals8.5.2026 16:00:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / May 8, 2026 / TruMerit, a global leader in healthcare workforce development and credential verification, today announced that it has issued its first verifiable digital credentials to healthcare professionals through a new partnership with Credivera, marking a major step forward in secure, portable credential verification for the global healthcare workforce. The first group of digital credentials has been awarded to nurses and other healthcare professionals who successfully passed TruMerit's global certification examinations over the last year. These include the Certified Global Nurse credential and credentials tailored for nurses and other healthcare workers specializing in rehabilitation care. These secure credentials can now be stored, managed, and shared digitally, allowing employers, regulators, and licensing authorities to instantly verify professional qualifications. Through Credivera's secure credential exchange platform, TruMerit credential
MicroVision and Avular Collaborate to Advance Autonomous Sensing and Drone Integration for Next-Generation Infrastructure Applications7.5.2026 22:05:00 CEST | Press release
Integrated lidar and modular drone platforms enable scalable autonomy, mapping, and navigation across complex real-world environments REDMOND, WA AND EINDHOVEN, THE NETHERLANDS / ACCESS Newswire / May 7, 2026 / MicroVision, Inc., (Nasdaq:MVIS), a leader in advanced perception solutions, today announced the signing of a Memorandum of Understanding (MoU) with Avular Innovations B.V. to integrate their technologies and accelerate the development of next-generation autonomous systems for civil infrastructure and global commercial applications. By combining MicroVision's high-performance, solid-state lidar, optimized for reduced energy usage and increased operational efficiency, with Avular's modular drone platforms and system integration expertise, the companies are creating a flexible, scalable solution designed to address real-world operational challenges across global markets. The collaboration focuses on delivering advanced capabilities, including autonomous mission execution in GPS-de
Innodata Reports Record First Quarter 2026 Results7.5.2026 22:05:00 CEST | Press release
Revenue Up 54% Year-Over-Year, Beats Consensus by 18% Adjusted EBITDA of $25.0 Million Beats Consensus by 139%; Adjusted Gross Margin Expands to 47% Raises Full-Year 2026 Revenue Growth Guidance to ~40% or More, Up From ~35% or More Announces New Engagements With Big Tech Company Expected to Generate Approximately $51 Million of Revenue in 2026 NEW YORK, NY / ACCESS Newswire / May 7, 2026 / INNODATA INC. (Nasdaq:INOD) today reported results for the first quarter ended March 31, 2026. Revenue of $90.1 million, representing 54% year-over-year revenue growth. Adjusted Gross Profit of $42.6 million, representing Adjusted Gross Margin of 47%.* Adjusted EBITDA of $25.0 million, or 28% of revenue, an increase of $12.3 million from $12.7 million in the same period last year.* Net income of $14.9 million, or $0.46 per basic share and $0.42 per diluted share, compared to net income of $7.8 million, or $0.25 per basic share and $0.22 per diluted share, in the same period last year. Cash, cash equ
Ostathi, Operated by UniHouse, Pioneers the Middle East's First Digital Infrastructure Linking Structured Workforce Development to Verified Income7.5.2026 18:30:00 CEST | Press release
World Bank and Jordan Ministry of Digital Economy-Funded Programme - Delivering the Region's First Auditable Connection Between Structured Capacity Development and Verified Income LONDON, UK / ACCESS Newswire / May 7, 2026 / Ostathi, owned and operated by UniHouse, today announced the live national deployment of a proprietary digital ledger infrastructure in Jordan - a first-of-its-kind system across the Middle East and Africa that connects an individual's structured capacity development, competency certification, gig economy and marketplace participation, and income generation into a single, auditable digital chain, integrated directly with regulated national fintech platforms. Ostathi Jordan - live deployment under the World Bank Youth, Technology and Jobs programme in partnership with Jordan's Ministry of Digital Economy and Entrepreneurship. The deployment is funded under the World Bank Youth, Technology and Jobs (YTJ) Project in partnership with Jordan's Ministry of Digital Econom
Loar Holdings Inc. Reports Q1 2026 Record Results and Upward Revision to 2026 Outlook7.5.2026 14:30:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 7, 2026 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reported record results for the first quarter of 2026. First Quarter 2026 Net sales of $156.1 million, up 36.1% compared to the prior year's quarter. Net income of $11.1 million, compared to $15.3 million for the prior year's quarter, primarily resulting from higher interest, higher non-cash amortization of acquired intangible assets, and the non-recurring non-cash recognition of inventory step-up related to the LMB and Harper Engineering acquisitions. Diluted earnings per share of $0.12 compared to $0.16 for the prior year's quarter, primarily resulting from higher interest, higher amortization of acquired intangible assets, and the non-recurring non-cash recognition of inventory step-up related to the LMB and Harper Engineering acquisitions. Adjusted EBITDA of $63.2 million, up 46.6% compared to the prior year's quarter. Net income margin of 7.1% compared t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom